晚期非小细胞肺癌整体治疗策略专题解读精选.ppt

* * * * Reference 1: P8 * Reference 1: P8 * Reference 1: P8-9 * Reference 1: P10 * Reference 1: P10 * Reference 1: P6 * Reference 7: P3856 Reference 8: P847 Reference 9: P348 * Reference 7: P3852 Reference 8: P847 * JMDB研究是是迄今样本最大且唯一入组1600例、晚期非小细胞肺癌一线治疗的前瞻性、随机、双盲、全球多中心的III期研究。 * * Reference 1: P6 * * Reference 10: P1335 Reference 11: P966 Reference 12: P 5233 * * * 889 is the intention to treat population (ITT) * * Reference 1: P6 * * * * * Reference 17: P953 * Reference 17: P954 * Reference 1: P7 * * Reference 19: P2542 Reference 20: P1227 * 1. Roche data on file. 2. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol 2009. Despite the small sample size and consequent low statistical power of this exploratory analysis, the final OS analysis for the subgroup of Asian patients in the AVAiL trial demonstrates an improvement in median OS in both Avastin arms compared with the placebo arm. The improvement in OS observed in Avastin-treated Asian patients in the AVAiL trial is greater than that observed in the overall AVAiL patient population. 1. Roche data on file. 2. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol 2009. Despite the small sample size and consequent low statistical power of this exploratory analysis, the final OS analysis for the subgroup of Asian patients in the AVAiL trial demonstrates an improvement in median OS in both Avastin arms compared with the placebo arm. The improvement in OS observed in Avastin-treated Asian patients in the AVAiL trial is greater than that observed in the overall AVAiL patient population. 1. Roche data on file. 2. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of